InspireMD
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4 Menorat Hamaor St, Tel Aviv, Tel Aviv,...Phone Number
+972 36917691Website
www.inspiremd.comRevenue
$10.8 MillionStock Symbol
NSPRIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About InspireMD
InspireMD, Inc., is a medical device company that is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases. InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable stroke free long-term outcomes. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB. The company is based in Tel Aviv, Israel.Explore more
InspireMD Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InspireMD your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if InspireMD is spiking on competitors!
Funding: Get notified immidiatlly once InspireMD has new funding data
Click to see if InspireMD had a recent Job posting/layoffs
Check if InspireMD has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on InspireMD recently announced quarterly report
Product Launch: Get notified when InspireMD launches new products
Congratulate Masked Content for being promoted to Masked Content at InspireMD
InspireMD, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at InspireMD
Find more new buyers
Company Profile Activity
Activity Insights
InspireMD is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
InspireMD is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about InspireMD.
InspireMD financials insights
Gather financial insights about InspireMD, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$11M
2025
Stock/Share Issuance
$40.1M
Stock/Share Issuance
$58M
InspireMD Tech Stack
A closer look at the technologies used by InspireMD
Most Recent Scoops
Project
InspireMD has submitted a Pre-Submission request to the FDA for the CGuard Prime 135 delivery system, with biocompatibility testing and the statutory review process identified as the key remaining variables that could influence the H1 2027 approval timeline, and the company has indicated that FDA agreement on an accelerated review could pull the approval timeline in earlier than currently guided.
Product Development, Compliance
Project
InspireMD has identified required design modifications and initiated validation and performance testing for the CGuard Prime 135 CAS delivery system, submitting an early Pre-Submission dossier to the FDA, with a current target timeline of H1 2027 for U.S. market re-entry and the potential for an earlier approval.
Product Development, Medical Research
Earnings
reported total operating expenses of $13.7 million for Q2 2026, an increase of $0.4 million compared to $13.3 million for Q2 2025, driven primarily by higher headcount-related expenses for the U.S. commercial team and increased development, clinical, and regulatory expenses related to SwitchGuard NPS and CGuard Prime 80 for TCAR, partially offset by lower general and administrative compensation expenses.
Earnings, Spending/Investment, Finance
Project
InspireMD has announced that its pending FDA submission for the CGuard Prime 80 platform for Transcarotid Artery Revascularization (TCAR), supported by the C-GUARDIANS II trial, is on track for a potential approval in Q4 2026, which would approximately double the company's addressable market by enabling use in both TCAR and Carotid Artery Stenting (CAS) procedures.
Clinical Operations
Hiring Plans
Hiring Plans
InspireMD News & Media
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of SeptemberInspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14th at 2:30 pm Eastern Time (ET).InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call August 17, 2026 8:30 AM EDTCompany ParticipantsMarvin Slosman - President, CEO & DirectorMichael Lawless -...InspireMD Reports Second Quarter 2026 Financial Results
- Company to host investor conference call today, August 17th, at 8:30am EDT -
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding InspireMD
Sign Up For FreeTo access detailed company insights
InspireMD, Inc., is a medical device company that is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases. InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outst... Read More
